Stefan Anker

Dr. Stefan D. Anker is a distinguished Professor specializing in Tissue Homeostasis in Cardiology & Metabolism (W3) at Charité University Medicine Berlin, a position he has held since June 2017. Dr. Anker earned his M.D. at Charité in 1993 and his Ph.D. from the National Heart & Lung Institute, Imperial College London, UK, in 1998. He was Professor of Cardiology & Cachexia Research (W2) at Charité from 2002 to 2014, and Professor of Innovative Clinical Trials (W3) in Göttingen from 2014 to 2017. With an extensive research portfolio, Dr. Anker has authored over 1,300 articles, earning recognition as a Highly Cited Researcher from 2015 to 2023. Notably, his work has garnered over 300,000 citations and achieved an h-index of 210. He has received numerous accolades for his contributions, including the prestigious 2018 Copernicus Prize of the German DFG & Polish FNP. He has also been honored with Doctor honoris causa titles from Medical University Wroclaw, Poland (October 2020), and Semmelweis University Budapest, Hungary (November 2021). Dr. Anker's research endeavors have been supported by grants and fellowships from institutions such as the NIH and the EU. He has secured funding for several IITs, including three ongoing projects funded by DZHK Germany and various industries. In addition to his academic achievements, Dr. Anker has held prominent leadership roles, serving as Vice President of the European Society of Cardiology (ESC) from 2016 to 2018 and as President of the ESC's Heart Failure Association (HFA) from 2012 to 2014. Dr. Anker's contributions to academia extend also to scientific journal leadership roles, as founding Editor-in-Chief of ESC Heart Failure from 2014 to 2022 and as the founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle, which he started in 2010. As President of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), Dr. Anker has been at the forefront of advancing research in these fields since 2008. He has been a member of more than 30 international clinical trial steering committees, many of which he either chaired or co-chaired (e.g. FAIR-HF, EMPEROR-Preserved & RESHAPE-HF2).